Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...

Rape in South Africa has been described a societal and public health crisis. It's estimated that 40,000 cases have been reported every year over the last decade. But research shows that most survivors ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

UNAIDS Executive Director Winnie Byanyima speaks during the Launch of HIV Prevention Project in Johannesburg, South Africa, ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

It will unfold alongside the G20 Leaders Summit, creating a two-tier stage where economic and health decisions mingle, ...

In a desperate measure to remain operational, RUPHA hospitals demanded that patients under SHA pay upfront. Effective ...

On 13 November 2025, Merck Sharp & Dohme LLC initiated a study is to learn if people who receive patritumab deruxtecan (also ...

Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion ...

Expert says delayed payments owed by the state to pharmaceutical suppliers have contributed to persistent stock-outs ...